699 results about "Screen method" patented technology

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that override the interferon(IFN)-induced cellular defense mechanisms against viral infection. In particular, the present invention relates to screening assays that identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region (ISDR) and IFN-induced PKR protein kinase. The present invention more particularly relates to screening assays that identify agents which selectively inhibit the interaction between hepatitis C virus (HCV) nonstructural 5A protein (NS5A), which contains an ISDR, and IFN-induced PKR protein kinase. The interaction between the viral ISDR and IFN-induced PKR protein kinase results in the override of IFN-induced cellular defense mechanisms to combat viral infection. Therefore the agents identified using the assays of the invention may have utility as antiviral agents.

The present invention provides compositions and methods for treating pain, including neuropathic pain, by modulating the expression or activity of one or more components of the complement pathway. The present invention further provides screening methods to identify therapeutic agents for treating pain by screening for compounds capable of modulating the expression or activity of one or more components of the complement pathway.

The invention discloses a self-discharge screening method for a lithium ion phosphate battery, belongs to the technical field of lithium ion batteries, and aims to provide a method for effectively screening the lithium ion phosphate battery with high self-discharge rate by using shelving in a charging state. According to the technical key points, the method comprises the following steps of: adding laminar lithium nickel cobalt manganese oxide or spinel lithium nickel manganese oxide which comprises 0.5 to 5 weight percent of lithium ion phosphate and has high voltage platform into a lithium ion phosphate-containing compound positive electrode; assembling the lithium ion phosphate battery by taking graphite as a negative electrode; fully charging the battery and then shelving the battery at an ambient temperature of between 20 and 45 DEG C; recording voltages before and after the shelf and shelf time; calculating the voltage difference before and after the shelf or a voltage variation value in unit time; and determining a critical value of the voltage difference of the batteries with the high self-discharge rate which are shelved in the same period or voltage variation in the unit time, and determining that the self-discharge rate of the battery of which the voltage difference or the voltage variation value in the unit time is greater than the critical value is high.

The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic or toxic peripheral nerve lesion or pain including, for example, neuropathic pain, inflammatory and nociceptive pain by administering to a mammal in need thereof a compound that reduces the expression or activity of BH4. According to this invention, this reduction may be achieved by reducing the enzyme activity of any of the BH4 synthetic enzymes, such as GTP cyclohydrolase (GTPCH), sepiapterin reductase (SPR), or dihydropteridine reductase (DHPR); by antagonizing the cofactor function of BH4 on BH4-dependent enzymes; or by blocking BH4 binding to membrane bound receptors. The compounds of the invention may be administered alone or in combination with a second therapeutic agent. The invention also provides methods for diagnosing pain or a peripheral nerve lesion in a mammal by measuring the levels of BH4 or its metabolites in biological sample. Alternatively, pain or a peripheral nerve lesion may be diagnosed by measuring the levels or activity of any one of the BH4 synthetic enzymes in tissue samples of a mammal. Also disclosed are screening methods that make use of BH4 or BH4 synthetic enzymes, BH4-dependent enzymes, and BH4-binding receptors for the identification of novel therapeutics for the treatment, prevention, or reduction of pain.

Methods for identifying prodrug activity utilizing screens with microbial mutants, including null and conditional mutants, transiently gene-repressed microbes, and gene-overexpressing microbes, as well as pooled collections of these are provided. Effective prodrug antibiotics differentially kill or inhibit microbes overexpressing prodrug activating genes and allow non-expressing strains to grow and be readily identified. Methods for detecting prodrug antibiotic activity by detecting a lack of differential sensitivity of multidrug efflux mutant or deficient strains are also provided. Novel pharmaceutical compounds identified by the methods of the invention, pharmaceutical formulations, and methods for treating an infection comprising administering to a subject in need thereof an effective amount of a Compound of the Invention are also provided.

Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip and the separate determination of the states of individual cells. A microwell array comprises multiple wells and a coating layer on one of the principal surfaces of a base member, the wells being of a size permitting the entry of only a single cell into each well. A coating layer of a substance capable of binding to a substance produced by the cells contained in the wells is present on the principal surface around the wells. A method of screening for a target cell, comprises: causing specimen cells and a cell culture broth to be contained in the wells of the above microwell array; immersing the coating layer and the wells in the culture broth and culturing the cells in a state permitting the diffusion of substances in the culture broth from the wells into the coating layer; feeding a label substance binding specifically to a substance produced by a target cell present among the specimen cells onto the coating layer; and detecting the substance produced by the target cell that has bound to the substance in the coating layer by the label substance to specify the target cell.

Use of animal models of neurodegenerative disorders for establishment of preclinical diagnostic and therapeutic indices, and for screening methods to identify effective preclinical therapies.

The present invention relates to a class of small molecule hydroxamic acid compounds capable of inhibiting histone deacetylases (HDACs). The present invention also relates to methods of preparation of hydroxamic acid HDAC inhibitor compounds of the invention, which are N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, and their incorporation into pharmaceutical compositions and methods of administration. The present invention also relates to N-substituted-1,2,3,4-tetrahydroisoquinoline hydroxamic acid derivatives, which may be prepared as a hydroxamic acid HDAC inhibitor compound library that can be utilized in screening methods known in the art.

The invention relates, in part, to methods of using proteomic biomarkers to diagnose preeclampsia. In some aspects the invention, in part, relates to the detection of serpina-1 polypeptide and/or albumin polypeptide in samples from pregnant subjects. Samples from subjects may be compared to control samples to diagnose preeclampsia and/or to determine the onset, progression, or regression of preeclampsia in a subject. The invention also relates, in part, to screening methods to identify agents that can be used to treat preeclampsia and to determine the efficacy of a preeclampsia treatment. The invention, in part, also includes kits that are useful to diagnose and assess preeclampsia in a subject.

The invention provides an image bullet screen method. The method is characterized in that the bullet screen can be performed for the image, and the commenting operation can be directly performed for the image; space coordinates are added to the comment record, and the display position of the comment in the image is controlled, so that the comment display and interaction mode is greatly improved; the user information is added to the bullet screen comment, thus the recognition degree of a comment author can be improved, and the software interaction is increased; the image bullet screen displaying method is that the ever-increasing comments are displayed everywhere, and the comments can automatically disappear after being displayed for a while; therefore, commenting with a sarcastic tone is achieved in the image, and the image and the user comments for the image can be displayed well.

The invention provides a terminal screen control method. The method comprises the following steps that after a terminal detects that the time that human eyes stare at a terminal screen exceeds a given time, a screen lightening control signal is generated; and the terminal lightens the terminal screen according to the screen lightening control signal. The invention also provides the terminal. The terminal screen control method provided by the invention has the advantages that operation of a user and wastage of the terminal are reduced, electric quantity can be saved to certain degree, and the incidence caused by mistaken pressing is reduced.

The invention discloses a mobile communication terminal which is characterized in that the interface of the mobile communication terminal comprises a virtual function bond region which comprises a locking icon. The locking and unlocking function can be realized by dragging the locking icon. A sliding type unlocking screen method provided by the invention provides a good interface for users by the visual sliding operation, improves the interface operation method of the users and leads to the result that the users feel more humanization and friendliness of the interface.

A zooming method for a digital photography device with a touch screen, characterized in that: the touch screen provided by the digital photography device is used to input a zoom gesture, and the digital photography device is controlled in real time to perform a zoom operation according to the change of the zoom gesture. The zooming method of the digital photographic device with a touch screen of the present invention can control the digital photographic device to perform the zooming operation in real time according to the change of the zooming gesture, and can check the zooming effect in real time during the process of inputting the zooming gesture, which is convenient and intuitive. In addition, the use of the touch screen to input zoom gestures eliminates the need to add physical buttons on the digital photography equipment, saving equipment space.

The invention discloses a screening method of colorectal cancer treatment prognosis biomarkers. The screening method includes the following steps of: (1) making a primary search strategy for screening the biomarkers; (2) making a literature adopting and exclusion criterion; (3) analyzing data and primarily screening the biomarkers; (4) making evident grades; (5) making a high quality evident evaluation criterion; (6) performing grading retrieval and quality evaluation on biomarker clinic evident; (7) performing data analyzing and statistics on the biomarker clinic evident; (8) screening the prognosis biomarkers. The invention further provides the colorectal cancer treatment prognosis biomarkers obtained through screening according to the screening method, and the prognosis biomarkers include KRAS, TYMS, TYMS, EGFR, UGT1A1*28, DPYD, PIK3CA, ERCC1, PTEN, VEGFR, BRAF, GST P1, XRCC1, MTHFR, MSI and the like.

The present invention relates to methods for screening, identifying, and/or quantifying modulators of amyloid and/or aggregates, fibrils or components thereof, in particular modulators of amyloid β-peptide (Aβ) or Aβ fibrils. Aspects of the invention provide methods for screening putative modulators against an Amyloid target, in particular an Aβ target, so as to determine which modulators bind to or interact with the target, or interfere with the interaction of an indicator agent and the target. Particular aspects of the invention employ mass spectrometric methods for the screening of an Amyloid target against compound libraries, in particular mixtures of compounds or combinatorial libraries.